CN1788731A - 一种由川芎嗪和灯盏花素组成的复方注射制剂及其制备方法 - Google Patents
一种由川芎嗪和灯盏花素组成的复方注射制剂及其制备方法 Download PDFInfo
- Publication number
- CN1788731A CN1788731A CN 200410066087 CN200410066087A CN1788731A CN 1788731 A CN1788731 A CN 1788731A CN 200410066087 CN200410066087 CN 200410066087 CN 200410066087 A CN200410066087 A CN 200410066087A CN 1788731 A CN1788731 A CN 1788731A
- Authority
- CN
- China
- Prior art keywords
- injection
- preparation
- group
- breviscapine
- ligustrazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 title claims abstract description 57
- 238000002347 injection Methods 0.000 title claims abstract description 45
- 239000007924 injection Substances 0.000 title claims abstract description 45
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 title claims abstract description 34
- 150000001875 compounds Chemical class 0.000 title claims abstract description 29
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 239000008215 water for injection Substances 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 8
- 238000000108 ultra-filtration Methods 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000004907 flux Effects 0.000 claims description 3
- 210000004907 gland Anatomy 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000706 filtrate Substances 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 10
- 206010008118 cerebral infarction Diseases 0.000 abstract description 6
- 208000010125 myocardial infarction Diseases 0.000 abstract description 5
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 4
- 201000006474 Brain Ischemia Diseases 0.000 abstract description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract description 4
- 230000002490 cerebral effect Effects 0.000 abstract description 4
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 208000029078 coronary artery disease Diseases 0.000 abstract description 3
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 230000002526 effect on cardiovascular system Effects 0.000 description 9
- 208000024172 Cardiovascular disease Diseases 0.000 description 8
- 230000002085 persistent effect Effects 0.000 description 7
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000000302 ischemic effect Effects 0.000 description 6
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 5
- 230000003727 cerebral blood flow Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical group C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 229960000715 nimodipine Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- NPLTVGMLNDMOQE-UHFFFAOYSA-N carthamidin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229930190376 scutellarin Natural products 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000000283 vasomotion Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 剂量(mg /kg) | 动物数(n) | 灌注前压力(mmHg) | 灌注后压力(mmHg) |
模型组灯川组灯盏花组川芎嗪组尼莫地平组 | 10552 | 1010101010 | 16.7±0.616.8±0.517.0±0.4616.9±0.5217.1±0.53 | 16.7±0.6##4.65±1.81**13.69±2.1*12.18±3.7*6.36±1.99** |
组别 | 剂量/L | 心脏数(n) | SOD(U/mg) | MDA(nmol/g) |
空白对照组溶媒组灯川组灯盏花组川芎嗪组利多卡因组 | 0.1ml10mg5mg5mg15mg | 101010101010 | 10.9±0.711.7±0.912.5±0.5*12.6±0.7*12.7±0.5*#11.0±1.4 | 320.6±58.0306.9±59.8220.1±20.5**##226.3±30.2*##250.7±39.0#280.9±68.3 |
组别 | 剂量/kg | 动物数(n) | 梗死区/心室(%) | 梗死区/心脏(%) |
生理盐水组溶媒组灯川组灯盏花组川芎嗪组普萘洛尔组 | 3ml3ml10mg5mg5mg0.5mg | 101010101010 | 32.67±7.8535.59±6.8117.67±10.15**20.86±8.78**31.51±8.520.58±10.58** | 24.91±4.9527.84±4.7215.10±6.53**17.23±7.79*25.97±7.3116.18±8.98* |
组别 | 剂量(mg/(kg.d)) | 喘气持续时间(s) |
空白对照组灯川组(1∶2)灯川组(1∶1)灯川组(2∶1)灯盏花组川芎嗪组尼莫地平组 | 101010552 | 13.8±3.923.7±8.7***18.3±7.218.8±7.717.5±6.0**15.1±6.819.7±6.5*** |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100660879A CN100417388C (zh) | 2004-12-17 | 2004-12-17 | 一种由川芎嗪和灯盏花素组成的复方注射制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100660879A CN100417388C (zh) | 2004-12-17 | 2004-12-17 | 一种由川芎嗪和灯盏花素组成的复方注射制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1788731A true CN1788731A (zh) | 2006-06-21 |
CN100417388C CN100417388C (zh) | 2008-09-10 |
Family
ID=36786976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100660879A Expired - Fee Related CN100417388C (zh) | 2004-12-17 | 2004-12-17 | 一种由川芎嗪和灯盏花素组成的复方注射制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100417388C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101164546B (zh) * | 2006-10-19 | 2010-12-15 | 江苏康缘药业股份有限公司 | 一种通络止痛药物组合物及其制备方法与制备药物的用途 |
CN101961310A (zh) * | 2010-09-15 | 2011-02-02 | 河南辅仁怀庆堂制药有限公司 | 盐酸川芎嗪注射液配制工艺 |
CN101569641B (zh) * | 2008-04-30 | 2011-08-31 | 成都中医药大学 | 一种治疗缺血性中风的药物组合物及其制备方法 |
CN114917229A (zh) * | 2022-06-09 | 2022-08-19 | 广东顺德工业设计研究院(广东顺德创新设计研究院) | 川芎嗪在制备用于减轻缺血再灌注损伤的药物中的应用 |
-
2004
- 2004-12-17 CN CNB2004100660879A patent/CN100417388C/zh not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101164546B (zh) * | 2006-10-19 | 2010-12-15 | 江苏康缘药业股份有限公司 | 一种通络止痛药物组合物及其制备方法与制备药物的用途 |
CN101569641B (zh) * | 2008-04-30 | 2011-08-31 | 成都中医药大学 | 一种治疗缺血性中风的药物组合物及其制备方法 |
CN101961310A (zh) * | 2010-09-15 | 2011-02-02 | 河南辅仁怀庆堂制药有限公司 | 盐酸川芎嗪注射液配制工艺 |
CN114917229A (zh) * | 2022-06-09 | 2022-08-19 | 广东顺德工业设计研究院(广东顺德创新设计研究院) | 川芎嗪在制备用于减轻缺血再灌注损伤的药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100417388C (zh) | 2008-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yang | Acute human toxicity of macrocyclic lactones | |
US20130171262A1 (en) | Honey based compositions of a consistency that can be delivered to the respiratory system | |
CN1997383B (zh) | 含水母发光蛋白的组合物及使用它的方法 | |
CN1261798A (zh) | 含有育亨宾和精氨酸用于治疗勃起功能障碍的药物 | |
CN113144179B (zh) | 乌司他丁在制备防治重症新型冠状病毒肺炎药物中的用途 | |
CN105853999A (zh) | 干扰素λ的雾化吸入剂 | |
CN100417388C (zh) | 一种由川芎嗪和灯盏花素组成的复方注射制剂及其制备方法 | |
CN1882313A (zh) | 药物的薄荷醇溶液 | |
RU2408383C1 (ru) | Композиция с противоопухолевой и адаптогенной активностью (варианты) и лекарственный препарат на ее основе (варианты) | |
CN100377712C (zh) | 葫芦素脂质体组方及其制剂 | |
JP3247381B2 (ja) | 抗コレラトキシン剤 | |
CN100346797C (zh) | 一种由冰片和银杏叶提取物组成的复方注射制剂及其制备方法 | |
CN1287808C (zh) | 银杏叶提取物组合物 | |
CN1781490A (zh) | 一种由冰片和灯盏花素组成的复方注射制剂及其制备方法 | |
CN101327215A (zh) | 一种含有原小檗碱型生物碱的药物组合物 | |
Rotmensch et al. | Furosemide-induced forced diuresis in digoxin intoxication | |
CN101596203B (zh) | 紫丁香苷在制备治疗心脑血管疾病药物中的应用 | |
CN107737108A (zh) | 一种治疗心肌梗死后心室重塑的口服药物组合物 | |
CN100348216C (zh) | 一种由冰片和丹参提取物组成的复方注射制剂及其制备方法 | |
CN1785246A (zh) | 一种由丹参提取物和三七总皂苷组成的复方注射制剂及其制备方法 | |
CN1281212C (zh) | 西洋参茎叶总皂苷在制备治疗心肌炎的药物中的应用 | |
EP1203585B1 (en) | Anti-ischemic agent | |
CN100400054C (zh) | 一种由川芎嗪和三七总皂苷组成的复方注射制剂及其制备方法 | |
RU2282437C1 (ru) | Средство для лечения болезней суставов | |
CN107648249B (zh) | 去半乳糖替告皂甙在制备防治流感病毒感染的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: JIANGSU CAREFREE PHARMACEUTICAL Co.,Ltd. Assignor: Qin Yinlin Contract fulfillment period: 2008.10.10 to 2018.11.6 Contract record no.: 2008320000982 Denomination of invention: Compound injection preparation containing ligustrazine and breviscapine and its preparation method Granted publication date: 20080910 License type: Exclusive license Record date: 20081015 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.10.10 TO 2018.11.6; CHANGE OF CONTRACT Name of requester: JIANGSU KEFEIPINGMEDICINE CO., LTD. Effective date: 20081015 |
|
ASS | Succession or assignment of patent right |
Owner name: JIANGSU CAREFREE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: QIN YINLIN Effective date: 20120824 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120824 Address after: 210016 Jiangsu Province, Nanjing city Zhongshan Road No. 323, 2 (former banshanyuan No. 12 Building 1 layer 1) Patentee after: JIANGSU CAREFREE PHARMACEUTICAL Co.,Ltd. Address before: 210016 Jiangsu Province, Nanjing city Zhongshan Road No. 323, 2 (former banshanyuan No. 12 Building 1 layer 1) Patentee before: Qin Yinlin |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: JIANGSU CAREFREE PHARMACEUTICAL Co.,Ltd. Assignor: Qin Yinlin Contract record no.: 2008320000982 Date of cancellation: 20160613 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 210016 Jiangsu Province, Nanjing city Zhongshan Road No. 323, 2 (former banshanyuan No. 12 Building 1 layer 1) Patentee after: JIANGSU CAREPHAR PHARMACEUTICAL Co.,Ltd. Address before: 210016 Jiangsu Province, Nanjing city Zhongshan Road No. 323, 2 (former banshanyuan No. 12 Building 1 layer 1) Patentee before: JIANGSU CAREFREE PHARMACEUTICAL Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080910 Termination date: 20211217 |
|
CF01 | Termination of patent right due to non-payment of annual fee |